datopotamab deruxtecan + rilvegostomig

**Datopotamab deruxtecan + rilvegostomig** is an investigational intravenous combination therapy being studied for first-line treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high PD-L1 expression and no actionable genomic alterations[1][3][7].\n- **Datopotamab deruxtecan (Dato-DXd)** is an antibody-drug conjugate targeting TROP2 (trophoblast cell-surface antigen 2). It consists of a humanized anti-TROP2 monoclonal antibody conjugated via a stable linker to deruxtecan, a topoisomerase I inhibitor payload, allowing targeted cytotoxic delivery to TROP2-expressing tumor cells[2][6].\n- **Rilvegostomig (AZD2936)** is a recombinant bispecific monoclonal antibody, simultaneously targeting programmed cell death protein 1 (PD-1) and T cell immunoreceptor with Ig and ITIM domains (TIGIT), designed to enhance anti-tumor immune response beyond conventional checkpoint inhibition[3][7].\n\nThe combination aims to provide synergistic antitumor activity by directly killing TROP2-positive cancer cells and stimulating anti-tumor immunity via dual checkpoint blockade.

Brand names

None known (no marketed brand names for this combination as of the latest data)

Other names

datopotamab deruxtecan + rilvegostomig